CVC Technologies (4744) reported revenue of NT$145.3 million for Oct 2026, +100.8% year on year and +34.8% from the previous month. Revenue for Jan–Oct 2026 was NT$811.9 million (-16.5% year on year).
In Oct 2026, it ranked No. 57 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$145.3 million | +100.8% | +34.8% |
| Sep 2026 | NT$107.8 million | -14.6% | +19.0% |
| Aug 2026 | NT$90.6 million | +34.6% | +143.6% |
| Jul 2026 | NT$37.2 million | -34.2% | -53.1% |
| Jun 2026 | NT$79.3 million | -68.4% | +27.7% |
| May 2026 | NT$62.1 million | +25.8% | +25.1% |
| Apr 2026 | NT$49.6 million | -27.5% | -65.9% |
| Mar 2026 | NT$145.4 million | -30.1% | +413.2% |
| Feb 2026 | NT$28.3 million | -33.0% | -57.3% |
| Jan 2026 | NT$66.3 million | +112.9% | -81.1% |
| Dec 2025 | NT$350.4 million | +13.0% | +186.8% |
| Nov 2025 | NT$122.2 million | +8.1% | +68.8% |
| Oct 2025 | NT$72.4 million | -4.0% | -42.7% |
| Sep 2025 | NT$126.2 million | +77.5% | +87.4% |
| Aug 2025 | NT$67.3 million | -25.9% | +19.1% |
| Jul 2025 | NT$56.5 million | -21.3% | -77.5% |
| Jun 2025 | NT$250.7 million | +132.7% | +408.0% |
| May 2025 | NT$49.3 million | -54.1% | -27.9% |
| Apr 2025 | NT$68.5 million | -21.1% | -67.1% |
| Mar 2025 | NT$207.8 million | +83.2% | +391.3% |
| Feb 2025 | NT$42.3 million | +16.6% | +35.9% |
| Jan 2025 | NT$31.1 million | -69.9% | -90.0% |
| Dec 2024 | NT$310.2 million | +33.5% | +174.5% |
| Nov 2024 | NT$113 million | +4.6% | +49.9% |
| Oct 2024 | NT$75.4 million | -12.7% | +6.0% |
Jan–Oct 2026 cumulative: NT$811.9 million (-16.5% YoY)
Other Biotech & Medical companies
Compare with peers: CVC Technologies vs PEC / CVC Technologies vs Lotus Pharm / CVC Technologies vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
本期銷售組合較多連線設備,導致營收增加。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16